PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

Summary

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) is a clinical trial^[1].

Key Facts

• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) is in the country of South Africa^[2].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) is in the country of Tanzania^[3].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s instance of is recorded as clinical trial^[4].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s start time is recorded as +2021-06-30T00:00:00Z^[5].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s end time is recorded as +2022-05-30T00:00:00Z^[6].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s contributor to the creative work or subject is recorded as University of California, San Francisco^[7].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s main subject is recorded as tuberculosis^[8].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s number of participants is recorded as {'unit': '1', 'amount': '+75'}^[9].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s title is recorded as A Phase IIb, Open Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of Delpazolid in Combination With Bedaquiline Delamanid Moxifloxacin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Drug-sensitive Pulmonary Tuberculosis^[10].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s short name is recorded as DECODE^[11].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[12].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s ClinicalTrials.gov ID is recorded as NCT04550832^[13].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[14].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s research intervention is recorded as moxifloxacin^[15].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s research intervention is recorded as bedaquiline^[16].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s clinical trial phase is recorded as phase II clinical trial^[17].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s research site is recorded as Pollita Institute^[18].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s research subject recruitment status is recorded as not yet recruiting^[19].
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)'s study type is recorded as interventional study^[20].